TY - JOUR
T1 - International society of geriatric oncology chemotherapy taskforce
T2 - Evaluation of chemotherapy in older patients - An analysis of the medical literature
AU - Lichtman, Stuart M.
AU - Wildiers, Hans
AU - Chatelut, Etienne
AU - Steer, Christopher
AU - Budman, Daniel
AU - Morrison, Vicki A
AU - Tranchand, Brigitte
AU - Shapira, Iuliana
AU - Aapro, Matti
PY - 2007/5/10
Y1 - 2007/5/10
N2 - The elderly comprise the majority of patients with cancer and are the recipients of the greatest amount of chemotherapy. Unfortunately, there is a lack of data to make evidence-based decisions with regard to chemotherapy. This is due to the minimal participation of older patients in clinical trials and that trials have not systematically evaluated chemotherapy. This article reviews the available information with regard to chemotherapy and aging provided by a task force of the International Society of Geriatric Oncology (SIOG). Due to the lack of prospective data, the conclusions and recommendations made are a consensus of the participants. Extrapolation of data from younger to older patients is necessary, particularly to those patients older than 80 years, for which data is almost entirely lacking. The classes of drugs reviewed include alkylators, antimetabolites, anthracyclines, taxanes, camptothecins, and epipodophyllotoxins. Clinical trials need to incorporate an analysis of chemotherapy in terms of the pharmacokinetic and pharmacodynamic effects of aging. In addition, data already accumulated need to be reanalyzed by age to aid in the management of the older cancer patient.
AB - The elderly comprise the majority of patients with cancer and are the recipients of the greatest amount of chemotherapy. Unfortunately, there is a lack of data to make evidence-based decisions with regard to chemotherapy. This is due to the minimal participation of older patients in clinical trials and that trials have not systematically evaluated chemotherapy. This article reviews the available information with regard to chemotherapy and aging provided by a task force of the International Society of Geriatric Oncology (SIOG). Due to the lack of prospective data, the conclusions and recommendations made are a consensus of the participants. Extrapolation of data from younger to older patients is necessary, particularly to those patients older than 80 years, for which data is almost entirely lacking. The classes of drugs reviewed include alkylators, antimetabolites, anthracyclines, taxanes, camptothecins, and epipodophyllotoxins. Clinical trials need to incorporate an analysis of chemotherapy in terms of the pharmacokinetic and pharmacodynamic effects of aging. In addition, data already accumulated need to be reanalyzed by age to aid in the management of the older cancer patient.
UR - http://www.scopus.com/inward/record.url?scp=34249779624&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249779624&partnerID=8YFLogxK
U2 - 10.1200/JCO.2007.10.6583
DO - 10.1200/JCO.2007.10.6583
M3 - Review article
C2 - 17488981
AN - SCOPUS:34249779624
VL - 25
SP - 1832
EP - 1843
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 14
ER -